Lupus clinical trials at UCSF
2 in progress, 1 open to eligible people
Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
open to eligible people ages 5-17
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to <12 with LN.
San Francisco, California and other locations
VIBRANT: VIB4920 for Active Lupus Nephritis
Sorry, in progress, not accepting new patients
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
San Francisco, California and other locations
Our lead scientists for Lupus research studies include David Wofsy, M.D..
Last updated: